NST-628 for recurrent grade 4 brain tumors
Part of Cancer clinical trials.
This trial tests an experimental drug called NST-628 for people with a grade 4 brain tumor (glioblastoma) that has come back after standard treatments. The drug is taken as a pill and may help slow or stop tumor growth. You must be scheduled for surgery to remove the tumor, and your tumor tissue must show a specific marker.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a grade 4 brain tumor (glioblastoma) that has grown despite standard treatments like surgery and radiation.
- You are at least 18 years old.
- You are generally able to care for yourself (ECOG score 0-2).
- You can swallow pills whole without crushing or chewing.
- You have a tumor that can be measured on an MRI scan and are planning to have surgery to remove it.
- You have not had more than 2 previous lines of cancer treatment for this tumor.
- You have not had chemotherapy, radiation, or other cancer treatments within 28 days before starting the study drug.
- You do not have cancer that has spread outside the brain or to the spinal fluid.
- You do not have serious heart, lung, or eye conditions that could increase risk.
- You are not pregnant or breastfeeding, and you agree to use effective birth control during and after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection called BC008-1A for people with a grade 4 glioma (a type of brain cancer) that has come back after standard treatment. The goal is to see if the drug can help control the tumor and improve outcomes.
This trial tests an experimental drug, BMS-986504, for people with recurrent glioblastoma (a type of brain cancer). The drug targets a specific genetic change in the tumor. It aims to see if the drug can help shrink or slow the tumor.
This trial tests a new treatment called TX103 CAR-T cells for people with a grade 4 glioma (like glioblastoma) that has come back or gotten worse after standard treatment. The therapy uses your own immune cells that are specially trained to attack a marker called B7-H3 found on tumor cells.
This study tests FT536, a new cell-based treatment, for people with a specific type of brain cancer (WHO Grade 4 astrocytoma) that has come back after standard treatment. The trial combines the new therapy with surgery to see if it can help stop the cancer from growing further.
This trial tests an experimental cell therapy (MT027) for people with high-grade brain tumors that have come back or stopped responding to treatment. It targets a protein called B7-H3 found on tumor cells, aiming to attack the cancer.
This trial tests a combination of two experimental drugs, CTX-009 and CTX-471, for people whose glioblastoma has returned. The goal is to see if these drugs can help control the tumor.
Hear when a new Glioma, Recurrent High Grade trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.